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SUMMARY
We determined the effect of chronic continuous diazepam treatment on the spectral content o f  the 
EEG in rats. Diazepam was administered for 21 days using subcutaneously implanted silastic 
tubes, resulting in constant blood concentrations.
Diazepam caused a decrease in the power of the low frequency bands (1-8 Hz) and an increase in 
the power of the high frequency bands (21-40 Hz). These changes persisted during 21 days o f  
treatment and were no longer detected in a post drug control measurement on the 9 th day after 
removing the tubes.
No tolerance developed to the effect of diazepam on the spectral content o f  the EEG. This 
indicates that in 21 days there is no decline in the effect o f  interaction o f diazepam with the 
GABAa - benzodiazepine receptor complexes responsible for the power spectrum changes,
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INTRODUCTION
It is known that tolerance develops to the behavioural effects of benzodiazepines: e.g. in rats to 
the sedating effects, to the motor impairing effects and to the anticonvulsive activity [4,5]. A  
reduction in the course of time of the spectral changes in the EEG (i.e. a decrease in the power o f  
the low frequencies and an increase in the power of the high frequencies [1 ,2 ,1 1 ]) is reported in 
multiple dose regime studies [12,13,17]. However, it is clinical knowledge that the EEG changes 
induced by benzodiazepines persist during chronic treatment (W. van Emde Boas, personal 
communication). Tolerance development might depend on the dose regime [4,9,19]. Repeated 
dosages of a benzodiazepine in rats result in major fluctuations in the concentrations o f  the drug 
[7] due to the short half life time in these animals (± 1 hour for diazepam, [6 ]). In humans, 
repeated dosages result in more constant blood concentrations due to the long half life time (± 40
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hours, [10]). We investigated the effect of diazepam on the EEG of rats having constant blood
concentrations during 21 days. Silastic tubes containing diazepam were subcutaneously implanted,
allowing a continuous release [7,8,16,20]. During the treatment we repeatedly determined the
power spectrum of the EEG.
MATERIALS AND METHODS
Sixteen male WAG/Rij rats were used, age 10 months and weighing 350 ± 16 grams (mean ± 
SD) at the start o f  the experiment. Animals were maintained on a 12-12 hour light-dark cycle: 
lights off at 9 am. Rats were single housed in standard cages with ad libitum access to standard 
food and water,
Three electrodes were implanted under complete Hypnorm anaesthesia (Plastic Products 
Company, MS 333/2A). The coordinates related to bregma were; A 2.0, L 2.0; A -3.1, L 9,0. A  
ground electrode was placed above the cerebellum. Animals were allowed to recover one week. 
EEG signals were measured between 1 Hz and 100 Hz and recorded digitally with a sample 
frequency of 200 Hz. Recordings took place from 11 am until 1 pm. Two baselines were 
recorded.
Per animal we used 8 silastic tubes o f  8 cm (Dow Corning, 0.062 inch inner diameter; 0.095 inch 
outer diameter), each containing 100 mg of solid diazepam. Controls received empty tubes. 
Implantation and removal were carried out under ether anaesthesia. Experimental recording started 
24 hours after tube implantation. A  post-drug recording was taken 9 days after tube removal.
Total benzodiazepine activity in the blood was determined with a receptor binding assay. Blood 
samples of 100 \jiL were taken from the tail venes and hemolyzed in water. The samples were 
extracted in pentane/dichloormethane. Evaporated extract fractions were incubated during 90 min 
at 0° C with rat-brain membrane preparations and 3 nM [methyl-3H]diazepam, followed by rapid 
filtration. Specific benzodiazepine activity was expressed relative to the activity on day 2. 
Statistical analysis was performed by linear regression followed by a F-test of the slope.
The spectral content of the EEG was determined by Fast Fourier Transformation for 10 periods of  
3.2 sec of EEG during passive wakefulness. This state was defined as observed immobile 
behaviour together with low voltage and fast frequency EEG [1,2]. A mean spectrogram was 
constructed for each animal per recording day and expressed in standardized scores (z-scores). We 
determined the mean power in the deli a-band (1-4 Hz), the theta-band (4-8 Hz), the alpha-band 
(8-12 Hz) and the beta-band (12-40 Hz) [18]. Statistical analysis was performed by ANOVA for 
repeated measurements.
Fig. 1
Relative blood concentrations during 21 
days of diazepam treatment with 
subcutaneously implanted silastic tubes.
Concentration values are relative the 
activity on day 2. Mean’s and S.E.M.’s 
on five treatment days (2 , 4, 9, 18 and 
2 1 ) are given (n=8 animals with 8 tubes 
of 8 cm each). The slope obtained by 
linear regression is not significantly 
different from zero (F-test; p=0.6).
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The diazepam output from the implanted tubes was 17.6 ± 1 . 6  mg per animal per day (mean ±  
SD, n=8 animals with 8 tubes). The total benzodiazepine concentrations in the blood were 
constant during the 21 days (fig 1). A  blood sample taken on day 2 analyzed by HPLC showed 
that the absolute concentration of diazepam was 0.7 jjM (200 ng/ml) and o f its main metabolite 
desmethyldiazepam was 1.2 juM (336 ng/ml).
The effects of these constant blood concentrations on the frequency bands o f  the EEG power 
spectra are presented in Fig. 2. During 21 days of treatment we found' a decrease in the mean 
power of the low frequency bands (delta: F I ,15=27,92, p<0.0001 and theta: F I ,15=17.96, 
p=0.0008) and an increase in the high frequency band (beta: Fl,15=47.15, p<0.0001), N o drug- 
day interaction was found. No differences were found on the baseline days nor on the 9th day 
after removal of the tubes between the control group and the experimental group.
power (z -sco re s )
0.75
0.50
0.25
-10
pre
0 10 
treatment
20 30
post
day
-10
pre
0 10 20 
treatment
30
p o s t
day
Fig. 2 .
Effects of diazepam treatment during 21 days on the EEG frequency bands. Data points are given  
for controls (open circles, n=8) and for diazepam treated rats (filled circles, n=8).
Mean power is expressed in z-scores (mean’s and S.E.M.’s) on two baseline recording days (-10 
and -5), five treatment days (1, 3, 8, 18 and 21) and one post-treatment day (30).
Data are given for the delta-band (1-4 Hz), theta-band (4-8 Hz), alpha-band (8-12 Hz) and beta- 
band (12-40 Hz). On all treatment days diazepam induces a decrease in the delta- and the theta- 
band and an increase in the beta-band (ANOVA p<0.0008). N o drug-day interaction was found.
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DISCUSSION
Blood concentrations remained constant during 21 days of implantation of silastic tubes with 
diazepam. This observation confirms earlier reports using this method [7].
The spectral content of the EEG was determined of EEG during passive wakefulness, a state 
known to be sensitive to drug effects [1]. During the entire treatment a decrease in the power of 
the low frequency bands and an increase in the power of the high frequency band was found. 
These changes are characteristic of single dose treatment with benzodiazepines [1,2,11]. During 
the treatment period no tolerance developed to the changes in the power spectrum. This 
observation confirms clinical knowledge that the EEG changes induced by benzodiazepines persist 
during chronic treatment. Humans, using benzodiazepines chronically, are likely to have fairly 
constant blood concentrations [10]. Tolerance development might be dependent on the dose 
regime, i.e. on changes in the concentration of the drug [4,9,19]. Sala et al. found that full 
tolerance developed to the increase in the beta band within 4 weeks using a single oral dose of 40 
mg/kg chlordiazepoxide per day in rats [17], We suggest that constant vs. fluctuating blood 
concentrations account for different results.
The changes in frequency bands o f  the EEG induced by diazepam reflect the interaction of the 
compound with the GABAa - benzodiazepine receptor complex. This was shown in a single dose 
study by Mandema et al. [11]. They found a perfect correlation between the benzodiazepine 
concentration producing half of the maximum EEG effect and the benzodiazepine affinity to the 
receptor site on the GABAa complex. This was determined in whole brain homogenates using 
tritiated flumazenil as the ligand [11], Different GABAa - benzodiazepine receptor subtypes exist 
in different brain areas, presumably serving different physiological functions [3,14]. In order to
%
clarify the mechanisms underlying tolerance development, it is important to know whether 
interactions of a benzodiazepine with its effector system remain intact during tolerance 
development. Our data indicate that in 21 days there is no decline of the effect of interaction of  
benzodiazepines with those receptor complexes that are responsible for the power spectrum 
changes. Three weeks o f  continuous treatment of rats with diazepam by the method described 
here did not alter the total benzodiazepine binding [16] but rather decreased the coupling between 
the GAB A  site and the benzodiazepine site [8]. It was found that the y2 subunit mRNA levels in 
the cortex were decreased [20]. The presence of the y2 subunit in the GABAa receptor causes the 
typical benzodiazepine effects in vitro [15]. Could it be that the effects of benzodiazepine 
treatment on the spectral content of the EEG are independent of the y2 subunit? Indeed, most of
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the subunits investigated did not change during chronic treatment [20]. In favour o f a difference
in receptors involved in behavioural and EEG changes, benzodiazepines disrupt the regular
relationship between EEG and behaviour [2]. The molecular basis underlying this pharmacological
dissociation might manifest itself in chronic studies.
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